regulator of G protein signaling 6Genealiases: GAP · HA117 · S914
Q-omics provides the consensus-scored RGS6 profile across patient tissues and cancer cell-line models. RGS6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RGS6 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RGS6 RNA expression shows 13,250 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where RGS6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS6 survival associations across molecular data types. RGS6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS6 RNA expression–survival associations across cancer types. High RGS6 expression shows unfavorable associations in LGG and UVM, but favorable associations in KIRC, LIHC, MESO and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RGS6 RNA expression.
This table summarizes RGS6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RGS6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS6 shows lower tumor expression in KICH, KIRC, THCA, KIRP and LUAD and higher tumor expression in HNSC. The KICH box plot shows higher RGS6 RNA expression in normal versus tumor tissue (log2 FC = −1.011, t-test p < 0.001).
This table shows molecular features associated with RGS6 in patient tissues and cancer cell lines. In patient samples, RGS6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
